Navigation Links
Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study

Angeles, California; founder and director-emeritus of The New England Center for Headache; and clinical investigator for the Phase II study.

Merck continues to anticipate filing a New Drug Application (NDA) for MK-0974 with the U.S. Food and Drug Administration in 2009.

About migraines

Migraine headaches impact approximately 28 million Americans, primarily women. Unlike a bad headache, migraines are characterized by attacks of intense, usually one-sided, throbbing head pain that can last from four to 72 hours. The pain associated with migraine is frequently accompanied by other associated symptoms, including nausea, vomiting and increased sensitivity to light and/or sound.

About Merck

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. For more information, visit www.merck.com.

Forward-Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new i
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
4. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
5. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents

Post Your Comments:
(Date:11/25/2009)...Newswire/ -- BioTrends Research Group, Inc. releas... report, the first in a multi-phase syndicated mar...or Ortho-Biotech,s Stelara, from product launch th...wave of the report provides quantitative informati...nformation from a subset of 20. The reports asses...
(Date:11/25/2009)...v. 25 Regado Biosciences, a privat...rombotic aptamers with active control agents, anno...ll be presenting at the Piper Jaffray 21st Annual ...l in New York City. Dr. Mazzo,s presentation will...nd will include an overview of the Company,s pipel...
(Date:11/25/2009)... Nov. 25 Swissray International, I...graphy ( ddR ) systems, announced today that its o...vestor with a long term view towards growing Swiss...ded all assets and intellectual property, as well ...ess and growth Swissray is now poised to move to t...
Breaking Medicine Technology:Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2Swissray International Announces New Ownership 2Cardiac Science Announces Third Quarter Results 6112 1Cardiac Science Announces Third Quarter Results 6112 2Cardiac Science Announces Third Quarter Results 6112 3Cardiac Science Announces Third Quarter Results 6112 4Cardiac Science Announces Third Quarter Results 6112 5Cardiac Science Announces Third Quarter Results 6112 6Cardiac Science Announces Third Quarter Results 6112 7Cardiac Science Announces Third Quarter Results 6112 8Cardiac Science Announces Third Quarter Results 6112 9Cardiac Science Announces Third Quarter Results 6112 10Cardiac Science Announces Third Quarter Results 6112 11Cardiac Science Announces Third Quarter Results 6112 12Cardiac Science Announces Third Quarter Results 6112 13Cardiac Science Announces Third Quarter Results 6112 14Cardiac Science Announces Third Quarter Results 6112 15Cardiac Science Announces Third Quarter Results 6112 16Cardiac Science Announces Third Quarter Results 6112 17Cardiac Science Announces Third Quarter Results 6112 18Cardiac Science Announces Third Quarter Results 6112 19Cardiac Science Announces Third Quarter Results 6112 20Forecast Looks Good for India Pharma Shows 6107 1Forecast Looks Good for India Pharma Shows 6107 2Forecast Looks Good for India Pharma Shows 6107 3Stipkala LLC to Sponsor Texas Life Science Conference November 12 13 2009 6102 1
...E PARK, N.C.--(BUSINESS WIRE)--Apr 3, 2007 -,Icage...ing a,planned meeting of the independent Data Moni...rial of senicapoc (formerly,ICA-17043) for the tre...ecommended that the trial be terminated because of...risis rate, the primary,endpoint. In making their ...
..., 2007--Treatment data from,Synovate Healthcare&rs...10,000 breast cancer patients in the UK could beco...lower death rates in,patients. The treatment was t...e edition of The Lancet (12 February 2007). Lower,...tched to the,aromotase inhibitor, Aromasin (exemes...
Other Medicine Technology:Icagen Terminates Phase III ASSERT Study 2Icagen Terminates Phase III ASSERT Study 3Over 10,000 UK Breast Cancer Patients Could Become Eligible Within,the Next Year for a Breast Cancer Therapy Showing Increased,Survival Rates, Reveals Synovate Healthcare’s European,Oncology Monitor 2Over 10,000 UK Breast Cancer Patients Could Become Eligible Within,the Next Year for a Breast Cancer Therapy Showing Increased,Survival Rates, Reveals Synovate Healthcare’s European,Oncology Monitor 3
(Date:11/27/2009)...v. 27 Team Garmin-Slipstream, the ... to ethical sporting and developing the next gener...t will become Team Garmin-Transitions with the add...he team. Transitions Optical is the world,s leadin...ost advanced photochromic technology in the widest...
(Date:11/27/2009)...les may reduce future disease burden, researchers ... -- Encouraging city dwellers to walk and bicycle ...lic health benefits than increased used of low-emi...The study compared the projected health effects in...s for London, England, and Delhi, India: business...
(Date:11/27/2009)...de; announced today that Spectrum Health (Grand Ra...ise orthopedic templating solution and its TraumaC... (PRWEB) November 27, 2009 -- Voyant Health&t...Rapids, Michigan) has licensed its TraumaCad Enter...aCad Extend workflow solution, to allow its orthop...
(Date:11/27/2009)...tive anatomy education apps from Modality and Lipp...es learning opportunities for iPhone and iPod touc...vember 27, 2009 -- Modality, Inc. and Lippincott...rs Kluwer Health, today announced the availability...ore. Clemente’s Anatomy, Rohen’s Photo...
(Date:11/26/2009)...cans living with diabetes will nearly double, incr...n 2034. Over the same period, spending on diabetes...336 billion, even with no increase in the prevalen... of Chicago report in the December issue of Diabe...overed by Medicare will rise from 8.2 million to 1...
Breaking Medicine News(10 mins):Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3
...ielman, M.D, Duke University Medical Center to sho...ting HIV infections than those which charge a smal...he testing center and is therefore a very efficien...the testing centre were 4 per day but after the fr...
... Internet and e-mail contribute towards strengthen...is has been revealed by the Pew Internet and Ameri...social relations get affected as a result of the I... in those networks do not live close to them, a Pe...
...ndian Government to produce some films with the Na...ht the achievements of Indian Scientists, //in add... in science. The name of the new initiative of the... The films will focus on nano-technology, the s...
...icist at the Max-Planck Institute for Dynamics and...which helped the researchers to understand the spr...s with the help of money trials.// He tracked...scientist fight against easily transmissible disea...
... common cancer next to breast cancer in women and ...y recognisation of cervical cancer would help in e...tality due to cervical cancer. A cytologic screeni...above the age of 18 years require yearly Pap smear...
...tion (APA) has released tips to help prevent the b...ion during the National Heart Month.// Research ha...ess will have an adverse impact on their health an... in effective ways that don't at the same time tak...
Other Medicine News:Health News:Free HIV Tests Brings Crowd to the Testing Centers 2Health News:Tracking the spread of disease with the help of money 2
...c diagnostic instrument that measures the refracti...e using a Hartmann-Shack wavefront sensor. The mea...-cylindrical) refractive errors and irregularities...on in the human eye. The WaveScan software uses th...
Zywave® II
ZYMAR™ 2.5 mL
REFRESH P.M.®
Medicine Products: